Intravitreal ranibizumab (Lucentis®) for the treatment of myopic choroidal neovascularization

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 247, Issue 3, 2009, Pages 311-318

  Konstantinidis, Lazaros ^a   Mantel, Irmela ^a   Pournaras, Jean Antoine C ^a   Zografos, Leonidas ^a   Ambresin, Aude ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Choroidal neovascularization; Myopia; Ranibizumab

Indexed keywords

RANIBIZUMAB;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INTERVENTION STUDY; MALE; MYOPIA; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFRACTION ERROR; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA FOVEA; RETINA NEOVASCULARIZATION; VISUAL ACUITY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS; MALE; MIDDLE AGED; MYOPIA, DEGENERATIVE; PROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY; VITREOUS BODY;

EID: 59749100158     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-008-0995-0     Document Type: Article

References (41)

1. Hampton GR, Kohen D, Bird AC (1983) Visual prognosis of disciform degeneration in myopia. Ophthalmology 90:923-926
2. Miller DG, Singerman LJ (2001) Natural history of choroidal neovascularization in high myopia. Curr Opin Ophthalmol 12:222-224. doi: 10.1097/00055735-200106000-00014
3. Avila MP, Weiter JJ, Jalkh AE, Trempe CL, Pruett RC, Schepens CL (1984) Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 91:1573-1581
4. Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ (1996) Etiology of choroidal neovascularization in young patients. Ophthalmology 103:1241-1244
5. Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, Lim JI, Menchini U, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld P, Schachat AP, Schmidt-Erfurth U, Sickenberg M, Singerman LJ, Slakter JS, Strong HA, Virgili G, Williams GA (2003) Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no. 3. Ophthalmology 110:667-673. doi: 10.1016/S0161-6420(02)01998-X
6. Secretan M, Kuhn D, Soubrane G, Coscas G (1997) Long-term visual outcome of choroidal neovascularization in pathologic myopia: Natural history and laser treatment. Eur J Ophthalmol 7:307-316
7. Mateo C, Moreno J, Rosales G, Lechuga M, Castillo R, Vaz F, Corcostegui B (2004) Two-year results of macular translocation with scleral infolding in myopic choroidal neovascularisation. Semin Ophthalmol 19:29-42. doi: 10.1080/08820530490520013
8. Fujii GY, Humayun MS, Pieramici DJ, Schachat AP, Au Eong KG, de Juan E Jr (2001) Initial experience of inferior limited macular translocation for subfoveal choroidal neovascularization resulting from causes other than age-related macular degeneration. Am J Ophthalmol 131:90-100. doi: 10.1016/S0002-9394(00)00769-8
9. Ruiz-Moreno JM, de la Vega C (2001) Surgical removal of subfoveal choroidal neovascularisation in highly myopic patients. Br J Ophthalmol 85:1041-1043. doi: 10.1136/bjo.85.9.1041
10. Kobayashi H, Kobayashi K (2000) Radiotherapy for subfoveal neovascularisation associated with pathological myopia: A pilot study. Br J Ophthalmol 84:761-766. doi: 10.1136/bjo.84.7.761
11. Liu DT, Lam DS, Chan WM (2004) Selective occlusion of subfoveal choroidal neovascularization in pathologic myopia using a new technique of ingrowth site treatment. Am J Ophthalmol 137:383 author reply 383-386. doi: 10.1016/j.ajo.2003.10.015
12. Costa RA, Calucci D, Teixeira LF, Cardillo JA, Bonomo PP (2003) Selective occlusion of subfoveal choroidal neovascularization in pathologic myopia using a new technique of ingrowth site treatment. Am J Ophthalmol 135:857-866. doi: 10.1016/S0002-9394(02)02257-2
13. Montero JA, Ruiz-Moreno JM (2007) Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: A pilot study. Br J Ophthalmol 91:131-133. doi: 10.1136/bjo.2006.106526
14. Chan WM, Lai TY, Wong AL, Liu DT, Lam DS (2007) Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: A pilot study. Br J Ophthalmol 91:174-179. doi: 10.1136/bjo.2006.103606
15. Rakic JM, Lambert V, Devy L, Luttun A, Carmeliet P, Claes C, Nguyen L, Foidart JM, Noel A, Munaut C (2003) Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 44:3186-3193. doi: 10.1167/ iovs.02-1092
16. Otani A, Takagi H, Oh H, Koyama S, Ogura Y, Matumura M, Honda Y (2002) Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc Res 64:162-169. doi: 10.1006/mvre.2002.2407
17. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419-1431. doi: 10.1056/NEJMoa054481
18. Chan WM, Lai TY, Liu DT, Lam DS (2007) Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: Six-month results of a prospective pilot study. Ophthalmology 114(12):2190-2196. doi: 10.1016/ j.ophtha.2007.03.043
19. Hernandez-Rojas ML, Quiroz-Mercado H, Dalma-Weiszhausz J, Fromow-Guerra J, Amaya-Espinosa A, Solis-Vivanco A, Reyna-Castelan E, Abraham-Marin M, Martinez-Castellanos MA, Aiello LP (2007) Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 27:707-712
20. Laud K, Spaide RF, Freund KB, Slakter J, Klancnik JM Jr (2006) Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 26:960-963. doi: 10.1097/01.iae.0000240121.28034.c3
21. Mandal S, Venkatesh P, Sampangi R, Garg S (2007) Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization. Eur J Ophthalmol 17:620-626
22. Nguyen QD, Shah S, Tatlipinar S, Do DV, Anden EV, Campochiaro PA (2005) Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 89:1368-1370. doi: 10.1136/ bjo.2005.066431
23. Sakaguchi H, Ikuno Y, Gomi F, Kamei M, Sawa M, Tsujikawa M, Oshima Y, Kusaka S, Tano Y (2007) Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 91:161-165. doi: 10.1136/bjo.2006.099887
24. Tewari A, Dhalla MS, Apte RS (2006) Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia. Retina 26:1093-1094. doi: 10.1097/01.iae.0000254896.78766.74
25. Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS (2007) Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 91:157-160. doi: 10.1136/bjo.2006.096776
26. Steinbrook R (2006) The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 355:1409-1412. doi: 10.1056/NEJMp068185
27. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ (2007) Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114:2179-2182. doi: 10.1016/j.ophtha.2007.09.012
28. Rosenfeld PJ (2007) Intravitreal Avastin for choroidal neovascularisation in pathological myopia: The controversy continues. Br J Ophthalmol 91:128-130. doi: 10.1136/bjo.2006.101337
29. Holladay JT (1997) Proper method for calculating average visual acuity. J Refract Surg 13:388-391
30. Ohno-Matsui K, Yoshida T, Uetama T, Mochizuki M, Morita I (2003) Vascular endothelial growth factor upregulates pigment epithelium-derived factor expression via VEGFR-1 in human retinal pigment epithelial cells. Biochem Biophys Res Commun 303:962-967. doi: 10.1016/S0006-291X(03)00446-7
31. Ohno-Matsui K, Morita I, Tombran-Tink J, Mrazek D, Onodera M, Uetama T, Hayano M, Murota SI, Mochizuki M (2001) Novel mechanism for age-related macular degeneration: An equilibrium shift between the angiogenesis factors VEGF and PEDF. J Cell Physiol 189:323-333. doi: 10.1002/jcp.10026
32. Tong JP, Chan WM, Liu DT, Lai TY, Choy KW, Pang CP, Lam DS (2006) Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 141:456-462. doi: 10.1016/ j.ajo.2005.10.012
33. Kourlas H, Abrams P (2007) Ranibizumab for the treatment of neovascular age-related macular degeneration: A review. Clin Ther 29:1850-1861. doi: 10.1016/j.clinthera.2007.09.008
34. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N (2008) Randomized, double-masked, sham-controlled trial of Ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 145:239-248. doi: 10.1016/j.ajo.2007.10.004
35. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432-1444. doi: 10.1056/NEJMoa062655
36. Nagpal M, Nagpal K, Nagpal PN (2007) A comparative debate on the various anti-vascular endothelial growth factor drugs: Pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin). Indian J Ophthalmol 55:437-439
37. Mordenti J, Cuthbertson RA, Ferrara N, Thomsen K, Berleau L, Licko V, Allen PC, Valverde CR, Meng YG, Fei DT, Fourre KM, Ryan AM (1999) Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 27:536-544. doi: 10.1177/019262339902700507
38. Gaudreault J, Fei D, Beyer JC, Ryan A, Rangell L, Shiu V, Damico LA (2007) Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina 27:1260-1266
39. Ferrara N, Damico L, Shams N, Lowman H, Kim R (2006) Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26:859-870. doi: 10.1097/01.iae.0000242842.14624.e7
40. Olsen TW (2007) Treatment of exudative age-related macular degeneration: many factors to consider. Am J Ophthalmol 144:281-283. doi: 10.1016/ j.ajo.2007.05.005
41. Sayanagi K, Ikuno Y, Soga K, Wakabayashi T, Tano Y (2008) Marginal crack after intravitreal bevacizumab for myopic choroidal neovascularization. Acta Ophthalmol (Copenh) 85:50-54